Literature DB >> 23628358

Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.

N Dlamini1, N C Voermans, S Lillis, K Stewart, E-J Kamsteeg, G Drost, R Quinlivan, M Snoeck, F Norwood, A Radunovic, V Straub, M Roberts, A F J E Vrancken, W L van der Pol, R I F M de Coo, A Y Manzur, S Yau, S Abbs, A King, M Lammens, P M Hopkins, S Mohammed, S Treves, F Muntoni, E Wraige, M R Davis, B van Engelen, H Jungbluth.   

Abstract

Mutations in the skeletal muscle ryanodine receptor (RYR1) gene are a common cause of neuromuscular disease, ranging from various congenital myopathies to the malignant hyperthermia (MH) susceptibility trait without associated weakness. We sequenced RYR1 in 39 unrelated families with rhabdomyolysis and/or exertional myalgia, frequent presentations in the neuromuscular clinic that often remain unexplained despite extensive investigations. We identified 9 heterozygous RYR1 mutations/variants in 14 families, 5 of them (p.Lys1393Arg; p.Gly2434Arg; p.Thr4288_Ala4290dup; p.Ala4295Val; and p.Arg4737Gln) previously associated with MH. Index cases presented from 3 to 45 years with rhabdomyolysis, with or without exertional myalgia (n=12), or isolated exertional myalgia (n=2). Rhabdomyolysis was commonly triggered by exercise and heat and, less frequently, viral infections, alcohol and drugs. Most cases were normally strong and had no personal MH history. Inconsistent additional features included heat intolerance, and cold-induced muscle stiffness. Muscle biopsies showed mainly subtle changes. Familial RYR1 mutations were confirmed in relatives with similar or no symptoms. These findings suggest that RYR1 mutations may account for a substantial proportion of patients presenting with unexplained rhabdomyolysis and/or exertional myalgia. Associated clinico-pathological features may be subtle and require a high degree of suspicion. Additional family studies are paramount in order to identify potentially MH susceptible relatives.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23628358     DOI: 10.1016/j.nmd.2013.03.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  56 in total

1.  Understanding Symptoms in RYR1-Related Myopathies: A Mixed-Methods Analysis Based on Participants' Experience.

Authors:  Carlos Capella-Peris; Mary M Cosgrove; Irene C Chrismer; M Sonia Razaqyar; Jeffrey S Elliott; Anna Kuo; Magalie Emile-Backer; Katherine G Meilleur
Journal:  Patient       Date:  2020-08       Impact factor: 3.883

2.  Acute rhabdomyolysis induced by tonic-clonic epileptic seizures in a patient with glucose-6-phosphate dehydrogenase deficiency.

Authors:  Rocco Liguori; Maria Pia Giannoccaro; Elena Pasini; Patrizia Riguzzi; Maria Lucia Valentino; Giacomo Pietro Comi; Valerio Carelli; Nereo Bresolin; Roberto Michelucci
Journal:  J Neurol       Date:  2013-09-20       Impact factor: 4.849

Review 3.  Prominent myalgia-an important clue in the diagnosis of a muscle disorder.

Authors:  Puneet Jain; Vineet Sehgal
Journal:  World J Pediatr       Date:  2017-06       Impact factor: 2.764

4.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

5.  Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.

Authors:  J R Lopez; V Kaura; C P Diggle; P M Hopkins; P D Allen
Journal:  Br J Anaesth       Date:  2018-08-10       Impact factor: 9.166

Review 6.  A "crush" course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician.

Authors:  Devan R Cote; Eva Fuentes; Ali H Elsayes; Jonathan J Ross; Sadeq A Quraishi
Journal:  J Anesth       Date:  2020-05-18       Impact factor: 2.078

7.  JSA guideline for the management of malignant hyperthermia crisis 2016.

Authors: 
Journal:  J Anesth       Date:  2017-02-28       Impact factor: 2.078

8.  Comparison of Chlorantraniliprole and Flubendiamide Activity Toward Wild-Type and Malignant Hyperthermia-Susceptible Ryanodine Receptors and Heat Stress Intolerance.

Authors:  Kim M Truong; Isaac N Pessah
Journal:  Toxicol Sci       Date:  2019-02-01       Impact factor: 4.849

9.  Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings.

Authors:  Yuri Hosokawa; Douglas J Casa; Henry Rosenberg; John F Capacchione; Emmanuel Sagui; Sheila Riazi; Luke N Belval; Patricia A Deuster; John F Jardine; Stavros A Kavouras; Elaine C Lee; Kevin C Miller; Sheila M Muldoon; Francis G O'Connor; Scott R Sailor; Nyamkhishig Sambuughin; Rebecca L Stearns; William M Adams; Robert A Huggins; Lesley W Vandermark
Journal:  J Athl Train       Date:  2017-03-07       Impact factor: 2.860

Review 10.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.